Cargando…

Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China

BACKGROUND: It is uncertain whether the extra acquisition costs of atypical antipsychotics over typical antipsychotics are offset by their other reduced resource use especially in hospital services in China. This study compared the psychiatric-related health care resource utilization and direct medi...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Xiaoning, Wu, Jing, Jiang, Yawen, Liu, Li, Ye, Wenyu, Xue, Haibo, Montgomery, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419499/ https://www.ncbi.nlm.nih.gov/pubmed/25880803 http://dx.doi.org/10.1186/s12913-015-0819-y

Ejemplares similares

Health care resource use and direct medical costs for patients with schizophrenia in Tianjin, People’s Republic of China
por: Wu, Jing, et al.
Publicado: (2015)

Hospitalization and cost after switching from atypical to typical antipsychotics in schizophrenia patients in Thailand
por: Boonlue, Tuanthon, et al.
Publicado: (2016)

Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics
por: Pesa, Jacqueline A., et al.
Publicado: (2015)

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2006)

Association of Typical versus Atypical Antipsychotics with Symptoms and Quality of Life in Schizophrenia
por: Fujimaki, Koichiro, et al.
Publicado: (2012)

Adherence and persistence to typical and atypical antipsychotics in the naturalistic treatment of patients with schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2008)

Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients
por: Ascher-Svanum, Haya, et al.
Publicado: (2009)

Serum substance P levels in patients with chronic schizophrenia treated with typical or atypical antipsychotics
por: Nagamine, Takahiko
Publicado: (2008)

Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects
por: Choi, Kwang H, et al.
Publicado: (2009)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
por: Jeon, Sang Won, et al.
Publicado: (2017)

Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
por: Fu, Alex Z., et al.
Publicado: (2022)

Evaluation of Paraoxonase, Arylesterase and Malondialdehyde Levels in Schizophrenia Patients Taking Typical, Atypical and Combined Antipsychotic Treatment
por: Güneş, Mehmet, et al.
Publicado: (2016)

Onset of action of atypical and typical antipsychotics in the treatment of acute psychosis
por: Mousavi, Seyed Ghafur, et al.
Publicado: (2013)

New atypical antipsychotics for schizophrenia: iloperidone
por: Caccia, Silvio, et al.
Publicado: (2010)

Depot Typical Antipsychotics versus Oral Atypical Antipsychotics in Relapse Rate Among Patients with Schizophrenia: A Five -Year Historical Cohort Study
por: Ahmadkhaniha, Hamid-Reza, et al.
Publicado: (2014)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
por: O’Day, Ken, et al.
Publicado: (2013)

One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study
por: Ye, Wenyu, et al.
Publicado: (2012)

Comparative Treatment Patterns, Resource Utilization, and Costs in Stimulant-Treated Children with ADHD Who Require Subsequent Pharmacotherapy with Atypical Antipsychotics Versus Non-Antipsychotics
por: Sikirica, Vanja, et al.
Publicado: (2012)

Atypical antipsychotics in the treatment of early-onset schizophrenia
por: Hrdlicka, Michal, et al.
Publicado: (2015)

New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression
por: Orzelska-Górka, Jolanta, et al.
Publicado: (2022)

Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil
por: Barbosa, Wallace Breno, et al.
Publicado: (2018)

Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy
por: Nadkarni, Anagha, et al.
Publicado: (2013)

Mortality Rates in Users of Typical and Atypical Antipsychotics: A Database Study in Poland
por: Zagozdzon, Pawel, et al.
Publicado: (2016)

Severity in schizophrenia patients receiving atypical antipsychotic medications
por: Alam Fatmi1j, Syed Meraj, et al.
Publicado: (2022)

Health resource utilization, costs, and community treatment order status before and after the initiation of second-generation long acting-injectable antipsychotics in patients with schizophrenia in Alberta, Canada
por: Chue, P., et al.
Publicado: (2022)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
por: Zhu, Baojin, et al.
Publicado: (2008)

Should ‘typical’, first-generation antipsychotics no longer be generally used in the treatment of schizophrenia?
por: Leucht, Stefan, et al.
Publicado: (2021)

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
por: Furiak, Nicolas M, et al.
Publicado: (2009)

Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder
por: Yan, Tingjian, et al.
Publicado: (2020)

Adherence to Typical Antipsychotics among Patients with Schizophrenia in Uganda: A Cross-Sectional Study
por: Kule, Moses, et al.
Publicado: (2023)

Outpatient Antipsychotic Treatment and Inpatient Costs of Schizophrenia
por: Marcus, Steven C., et al.
Publicado: (2008)

Use of Conventional Antipsychotics and the Cost of Treating Schizophrenia
por: Lyu, Ramon R., et al.
Publicado: (2001)

Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients
por: Kamat, Siddhesh A, et al.
Publicado: (2015)

Neural Basis for the Ability of Atypical Antipsychotic Drugs to Improve Cognition in Schizophrenia
por: Sumiyoshi, Tomiki, et al.
Publicado: (2013)

Minimizing Cardiovascular Adverse Effects of Atypical Antipsychotic Drugs in Patients with Schizophrenia
por: Khasawneh, Fadi T., et al.
Publicado: (2014)

A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics
por: Gilca, Marilena, et al.
Publicado: (2014)

Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia
por: MacEwan, Joanna P., et al.
Publicado: (2016)

Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia
por: Pilon, Dominic, et al.
Publicado: (2017)

A Comparative Study of Sexual Dysfunction due to Typical and Atypical Antipsychotics in Remitted Bipolar-I Disorder
por: Nagaraj, Anil Kumar M., et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_c8see0b7d1ue5sbr3hngovpm1q